State of the art in anti-cancer mAbs
Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today,...
| Main Authors: | , , |
|---|---|
| Format: | info:ar-repo/semantics/artículo |
| Language: | Inglés |
| Published: |
2017
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.12123/548 https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y https://doi.org/10.1186/s12929-016-0311-y |
Similar Items: State of the art in anti-cancer mAbs
- Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
- Anticuerpos monoclonales : qué son y cómo cambiaron el rumbo de la inmunología
- Development and field evaluation of a competitive ELISA to detect specific antibodies against Anaplasma marginale
- Congenital neoplasms in cattle: A literatura review and multi-institutional case series
- A computational study of the interaction of the foot and mouth disease virus VP1 with monoclonal antibodies
- Production of functional bovine IL-22 in a mammalian episomal expression system